JPRN-UMIN000001267
Completed
Phase 2
Multicenter phase II trial of gemcitabine and S-1 for gallbladder cancer - Multicenter phase II trial of gemcitabine and S-1 for gallbladder cancer
agoya University Hospital0 sites20 target enrollmentJuly 25, 2008
Conditionsgallbladder cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- gallbladder cancer
- Sponsor
- agoya University Hospital
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The exclusion criteria are as follows: active infection. pregnant or lactating women, women of childbearging age. the patient inappropriate for entry onto this study in the judgment of the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaJPRN-UMIN000021484Clinical study group of Osaka university, Hepato-Biliary- Pancreatic group100
Completed
Phase 2
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine in advanced biliary tract cancer (GS-COMBI).Advanced biliary tract cancerJPRN-UMIN000001703Japanese Endoscopist & IVRists group for Biliary Tract Cancer (JEIBIC)62
Recruiting
Phase 2
PDAC-GS/GA-rP2JPRN-jRCTs051180122Kobayashi Syogo100
Recruiting
Phase 2
Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in patients with gemcitabine-refractory advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000007173Tokai University Hospital Kanagawa Cancer Center90
Completed
Phase 2
Phase II study of gemcitabine/S-1 combination therapy in patients with non-resectable advanced biliary tract cancernon-resectable biliary tract cancer or recurrent biliary tract cancer post surgical treatmentJPRN-UMIN000000792Kyoto University Hospital25